lifevantage glp 1 Study backs LifeVantage's supplement stack for gene-activated weight management and healthy aging That’s a wrap for Day

The largest meta-analysis to date, comprising 13 cardiovascular outcome trials involving 83,258 patients with and without diabetes, confirmed that GLP-1 Ras significantly reduced major adverse cardiovascular events (MACEs), all-cause mortality, cardiovascular mortality, fatal and non-fatal strokes, coronary revascularization, and composite kidney outcomes [87]

This forerunner therapy was first approved in 2010 for the treatment of type 2 diabetes, for which it carried the brand name Victoza

doi: 10.1016/j.tree.2016.03.006 109 ShawR

This helps PWS patients reach their weight loss goals

What real obesity care looks like Viral trends and fads are rarely a successful route to sustained and healthy weight loss

BMC Med 2010